Yes it overvalued when compared to a biotech like Novogen which has much better downside protection and massive upside.
Still, once they start selling their product the risk profile will change. People are just getting in early.
I would buy them on a pull back to $4.50.
Looks like my $6 close target will get pretty close.
????????, page-3
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)